Cascadian Therapeutics, Inc.
CASC
CASC was delisted on the 8th of March, 2018.
91 hedge funds and large institutions have $152M invested in Cascadian Therapeutics, Inc. in 2017 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 30 increasing their positions, 19 reducing their positions, and 5 closing their positions.
4,900% more call options, than puts
Call options by funds: $50K | Put options by funds: $1K
260% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 5
58% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 19
15% more funds holding
Funds holding: 79 → 91 (+12)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less capital invested
Capital invested by funds: $166M → $152M (-$14.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.95M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$2.72M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
+$2.66M |
| 4 |
Goldman Sachs
New York
|
+$2.53M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$2.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$12.3M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$5.41M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1M |
| 4 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
-$170K |
| 5 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
-$164K |
CASC Hedge Fund Activity: Q4 2017 in Review
91 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q4 2017, worth a combined $152M — down 8.5% from $166M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CASC positions and 5 closed out — a net gain of 13 holders — while 30 added to existing stakes and 19 trimmed.
The largest buyer was BlackRock, adding an estimated $2.95M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $12.3M sold.
- 91 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q4 2017, up from 79 in Q3 2017.
- Funds reported $152M of Cascadian Therapeutics, Inc. stock for Q4 2017, down 8.5% quarter-over-quarter.
- 18 funds opened new Cascadian Therapeutics, Inc. positions in Q4 2017 and 5 closed out, a net change of +13 holders.
- The largest Cascadian Therapeutics, Inc. buyer in Q4 2017 was BlackRock, an estimated $2.95M added.
- The largest Cascadian Therapeutics, Inc. seller in Q4 2017 was EcoR1 Capital, an estimated $12.3M sold.
Based on aggregated 13F filings for Q4 2017.